Therapy Areas: Inflammatory Diseases
US FDA has Granted Priority Review of the Teprotumumab Biologics License Application for the Treatment of Active Thyroid Eye Disease
...
Soligenix announces appointment of Jonathan Guarino as SVP and CFO
11 September 2019 - Biopharmaceutical company Soligenix Inc (Nasdaq: SNGX) disclosed on Wednesday that Jonathan Guarino has been appointed as the company's senior vice president and chief financi...
US FDA Grants Fast Track Designation to Nangibotide Development Programme for the Treatment of Septic Shock
5 September 2019 - - The US Food and Drug Administration has granted Fast Track designation to nangibotide development program for the treatment of septic shock, French biotechnology company Inotrem S...
Inotrem awarded FDA Fast Track Designation for Nangibotide development programme for septic shock
3 September 2019 - Biotechnology company Inotrem SA revealed on Tuesday the receipt of the US Food and Drug Administration (FDA) Fast Track designation for the nangibotide development programme for th...
Strekin AG raises CHF2.82m from Series A financing round
3 September 2019 - Swiss biopharmaceutical company Strekin AG reported on Monday that it has received CHF2.82m under its Series A financing round with private investors.The company said the funds will...
AstraZeneca achieves primary endpoint in anifrolumab phase III Tulip two trial
2 September 2019 - United Kingdom-based AstraZeneca has achieved its primary endpoint in the phase III Tulip two trial of new medicine anifrolumab for systemic lupus erythematosus, it is reported toda...